5.3507

1.28% -0.0693

Bioage Labs Inc (BIOA)

Overview News Price History Option Chain Financials Discussions Forecast

Bioage Labs Inc stock is traded at $5.3507, with a volume of 331.21K. It is down -1.28% in the last 24 hours and down -34.59% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Previous Close:

$5.42

Open:

$5.48

24h Volume:

331.21K

Relative Volume:

0.34

Market Cap:

$245.58M

Revenue:

$10.32M

Net Income/Loss:

$-89.93M

P/E Ratio:

-2.2235

EPS:

-2.4064

Net Cash Flow:

$-88.63M

1W Performance:

-13.84%

1M Performance:

-34.59%

6M Performance:

-68.47%

1Y Performance:

-5.96%

1-Day Range:

$5.31

$5.50

1-Week Range:

$5.36

$6.47

52-Week Range:

$5.04

$25.95

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1051)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

510-806-1445

Address

5885 HOLLIS STREET, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	5.3507	245.58M	10.32M	-89.93M	-88.63M	-2.4064
TAK Takeda Pharmaceutical Co Adr	19.63	62.71B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.25	48.11B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.965	43.82B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	78.69	32.51B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	548.81	23.54B	3.17B	1.29B	1.01B	27.09

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-12-26	Initiated	UBS	Neutral
May-27-26	Initiated	Roth Capital	Buy
May-13-26	Initiated	BTIG Research	Buy
Mar-27-26	Initiated	Needham	Buy
Feb-25-26	Initiated	Oppenheimer	Outperform
Feb-18-26	Upgrade	Jefferies	Hold → Buy
Jan-27-26	Initiated	Piper Sandler	Overweight
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-22-25	Upgrade	Citigroup	Neutral → Buy
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

Oct 02, 2026

BioAge Labs Initiates Dosing in Phase 2 QUELL-DME Trial for Diabetic Macular Edema - Kalkine Media

Oct 02, 2026

Sep 21, 2026

BioAge Labs (Nasdaq:BIOA)Stock Analysis - Simply Wall Street

Sep 21, 2026

Sep 14, 2026

BioAge Labs (NasdaqGS:BIOA) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 14, 2026

Sep 11, 2026

BioAge Labs at Cantor conference: shifts focus to retina By Investing.com - Investing.com Canada

Sep 11, 2026

Sep 09, 2026

Transcript : BioAge Labs, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11 - marketscreener.com

Sep 09, 2026

BIOA: Phase II trials for BGE-102 target DME and metabolic diseases, with pivotal data expected next year - TradingView

Sep 09, 2026

Sep 08, 2026

A daily pill for diabetic eye disease enters a Phase 2 trial - Stock Titan

Sep 08, 2026

Sep 05, 2026

BioAge Labs remains a buy despite 40% drop, bac... - Pluang

Sep 05, 2026

BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off (BIOA) - Seeking Alpha

Sep 05, 2026

Sep 02, 2026

BioAge Labs to Present at Upcoming Investor Conferences - markets.businessinsider.com

Sep 02, 2026

BioAge Labs to Present at Upcoming Investor Conferences - Yahoo Finance

Sep 02, 2026

Sep 01, 2026

Bioage Labs Market Sentiment - Benzinga España

Sep 01, 2026

Aug 26, 2026

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - qz.com

Aug 26, 2026

Aug 15, 2026

354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC - MarketBeat

Aug 15, 2026

Aug 14, 2026

BioAge Labs, Inc.: Shareholders Board Members Managers and Company Profile | US09077V1008 - marketscreener.com

Aug 14, 2026

Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat

Aug 13, 2026

Aug 12, 2026

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 12, 2026

Aug 11, 2026

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat

Aug 11, 2026

BIOA Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest ReliefEarnings Stability Report - vinanet.vn

Aug 11, 2026

Aug 10, 2026

We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo

Aug 10, 2026

BioAge Labs (BIOA) Retreats 2.3% Toward Key Support as Momentum FadesRSI Overbought Alerts - vinanet.vn

Aug 10, 2026

Aug 08, 2026

Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Cuts Target Price to $20 - Moomoo

Aug 08, 2026

Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 08, 2026

Aug 07, 2026

Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV) - The Globe and Mail

Aug 07, 2026